Park Jae-hyun, CEO of Hanmi Pharmaceutical. (Photo: Hanmi Pharmaceutical)

 

 

[Alpha Biz= Paul Lee] Park Jae-hyun, CEO of Hanmi Pharmaceutical, has clarified his position regarding the recent conflict with Shin Dong-kuk, chairman of Hanyang Precision and a major shareholder of Hanmi Pharmaceutical, denying allegations that he met Shin to seek support for his reappointment.

Park made the remarks on March 4 during a town hall meeting with about 100 employees, where he addressed the controversy directly.

“Following recent media interviews, various interpretations have emerged inside and outside the company, and the major shareholder side has referred to me as someone who came to request reappointment,” Park said. “To be clear, on the day of the meeting that was recorded, I did not go there to ask for my reappointment.”

Park said the roughly 40-minute meeting primarily focused on what he described as improper interference in management.

According to Park, Shin had characterized the entire Hanmi Pharmaceutical Group as if it were an organization riddled with wrongdoing, prompting him to protest.

“I told him that such remarks were inappropriate and that they were insulting,” Park said, adding that any mention of reappointment arose only within the broader context of that discussion.

Park emphasized that his personal position regarding reappointment is not his main concern.

“Whether I am reappointed or not does not matter to me,” he said. “However, I will do everything in my power to prove that Hanmi is not the kind of corrupt organization it has been portrayed as.”

He added that defending the company’s reputation is also a matter of personal commitment.

“This is about protecting the honor of Hanmi Group and demonstrating the value of the 33 years I have devoted to my life at Hanmi,” he said.

Park also raised three public questions directed at Shin.

First, he questioned why Shin allegedly called an executive accused of sexual misconduct and informed the individual about an internal investigation before the company’s official inquiry had even begun.

Park also referred to remarks in which Shin compared himself to the president, saying, “I didn’t bypass the CEO. Why is it a problem to meet and listen to many people? Does a president work only with the prime minister?”

Park responded by asking whether such statements contradict Shin’s earlier commitment to maintaining a professional management system.

He further raised concerns about a change in raw materials used for Rosuzet, Hanmi Pharmaceutical’s cholesterol treatment.

“Can we be certain that switching to an unverified Chinese-sourced raw material would pose no problems?” Park said. “We are already receiving inquiries asking whether it is still safe to continue prescribing and taking the drug.”

 

 

 

[ⓒ AlphaBIZ. 무단전재-재배포 금지]